Zentalis Pharmaceuticals, Inc. (ZNTL) Misses Q2 EPS by 82c

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($1.85), $0.82 worse than the analyst estimate of ($1.03).

For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance